Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S2 pseudogene 52 (RPS2P52) is a non-coding DNA sequence in the human genome that shares high sequence similarity with the functional ribosomal protein S2 gene but lacks the capability to produce a functional protein[5][8]. Such pseudogenes result from gene duplication, retrotransposition, or incomplete copying events, and their sequences often contain disabling mutations that prevent translation into a working protein. RPS2P52 does not participate in canonical ribosome synthesis, signaling, or known cellular functions. It is not recognized as a therapeutic target, receptor, enzyme, transporter, transcription factor, or disease biomarker. Its designation as a "pseudogene" indicates that it is not a protein-coding gene, but rather a genomic remnant of evolutionary origin[5][8]. Ribosomal protein pseudogenes, including RPS2P52, are commonly dispersed throughout the genome; they typically have no direct functional effects and are not included in clinical or pharmacological targeting[5]. There may be confusion or misidentification between protein-coding ribosomal subunits (such as RPS2) and their pseudogenes; only the protein-coding forms participate in ribosomal function or are occasionally implicated in disease[1][4][5]. The canonical ribosomal protein S2 (RPS2), not RPS2P52, is the true component of the 40S ribosomal subunit and plays roles in translation and ribosome assembly[1][4][9]. RPS2P52 should not be considered a valid therapeutic target. If you need structured information for the functional ribosomal protein S2, refer to "Ribosomal protein S2" (RPS2), a genuine protein-coding gene with known molecular and disease roles[1][4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S2 pseudogene 52 (RPS2P52).